Publications by authors named "Albert Thomas DiCioccio"
Article Synopsis
- Osteoarthritis pain management options are currently limited, and fasinumab, an anti-nerve growth factor monoclonal antibody, is being tested for its effectiveness in treating OA pain.
- Data from 12 clinical trials involving 7430 patients and 92 healthy volunteers were used to create a pharmacokinetic model to understand how fasinumab behaves in the body.
- The study found that fasinumab's concentration in the body varied based on body weight and dosage, with higher doses leading to increased bioavailability and different exposure levels among participants.
A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors.
Elena Gabriela Chiorean Patricia LoRusso Robert Matthew Strother Jennifer R Diamond Anne Younger Albert Thomas DiCioccio
Clin Cancer Res
June 2015
Purpose: Enoticumab (REGN421) is a fully human IgG1 monoclonal antibody that binds human Dll4 and disrupts Notch-mediated signaling. The main objectives of this trial were to determine the safety, dose-limiting toxicities (DLT), pharmacokinetics (PK), and recommended phase II dose (RP2D) of enoticumab.
Experimental Design: Enoticumab was administered intravenously, with dose escalations from 0.